MARATTO

article · Benha Medical Journal

Assessment of prognostic value FOXA1 Expression in breast carcinoma after neoadjuvant chemotherapy: Immunohistochemically Study

2024Open accessBenha University

Abstract

Background: Breast carcinoma is the most common malignant tumor and the leading cause of carcinoma death in women. Aim and objectives: to determine the expression of FOXA1 in breast carcinoma, to correlate the expression of FOXA1 with hormonal receptors (ER and PR), Her2neu, Ki67 and pathological response to chemotherapy. Patient and method: This retrospective study was carried on 100 cases included seven cases with bilateral breast cancer, eighty-six cases IDC, five cases ILC and fifty-six cases with positive axillary lymph nodes metastasis. It was performed on formalin-fixed paraffin-embedded tissue blocks of specimens, collected from Benha Pathology Department, Faculty of Medicine, Benha University, from the years (2013- 2019). Result: Concerning the pathological response were found that (40) cases showed complete pathological response and (13) cases has no pathological response out of them FOXA1 positivity (44 and 7 cases respectively). While for (ER), (89) cases are positive out of them (74) case FOXA1 positive, and (PR), (80) cases positive, FOXA1 positivity (68) out of them, however Her-2neu negative cases were (48) from them (41) case are FOXA1 positive. Fore Ki-67, fourteen (14) cases show low scoring, while (31) cases has intermediate score and (55) cases has high scoring, FOXA1 positivity out of them (14, 31, 33 cases respectively). Conclusion: FOXA1 is a marker of good prognosis in breast cancer as FOXA1 expression associated with complete pathological response, positive hormone receptors and low-intermediate Ki67.

Research topics

  • FOXO transcription factor regulation

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21608/bmfj.2024.252347.1966

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.